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PRELIMINARY RESULTS OF A PROSPECTIVE RANDOMIZED 
STUDY COMPARING RADICAL PROSTATECTOMY VERSUS
RADICAL PROSTATECTOMY ASSOCIATED WITH 
NEOADJUVANT HORMONAL COMBINATION THERAPY
IN T2_3 No Mo PROSTATIC CARCINOMA
WIM P. J. WITJES, CLAUDE C  SCHULMAN, a n d  FRANS M. J. DEBRUYNE FOR THE EUROPEAN
STUDY GROUP ON NEOADJUVANT TREATMENT OF PROSTATE CANCER
ABSTRACT
Objectives. To evaluate the short- and long-term effects of neoadjuvant hormonal treatment in locally con­
fined prostate cancer.
Methods. We report the preliminary results of 354 patients (199 with a clinical T2 tumor and 155 with a 
clinical T3 tumor) of whom 164 randomly received neoadjuvant total androgen deprivation using a luteinizing- 
hormone-releasing hormone (LHRH) analog (goserelin) plus flutamide for a period of 3 months.
Results. Serum prostate-specific antigen (PSA) levels and prostatic volume decreased from a mean of 19.9 ng/ 
mL and 37.7 cm3 to a mean of 0.8 ng/mL and 26.5 cm3 after 3 months of neoadjuvant therapy. ‘‘Clinical down- 
staging” was seen in 32% in the neoadjuvantiy treated group. ‘‘Pathological downstaging” percentages were 6% 
and 16% in the direct radical prostatectomy group and neoadjuvantly-treated group, respectively (P <0.01). In 
patients with clinical T2 tumors, a significant difference in number of positive margins was shown in favor of the 
neoadjuvantiy treated group (P <0.01). In patients with clinical T3 tumors, a significant difference could not be 
detected (P = 0.14). In 215 patients with a mean follow-up time of 15 months, the calculated 95% confidence 
intervals of mean time of PSA progression-free survival were 26 to 35 months in the neoadjuvantly-treated group 
and 28 to 37 months in the direct radical prostatectomy group, indicating no significant differences between 
treatment groups. However, follow-up time Is currently too short to draw definite conclusions.
Conclusions. These early data confirm high understaging percentages in clinical staging. The clinical rele­
vance of the statistically significant smaller numbers of patients with positive margins in the neoadjuvantiy 
treated group with a clinical T2 tumor will have to be confirmed when further follow-up allows an accurate 
evaluation of time to PSA progression, local recurrence, and distant metastases, Presently, neoadjuvant 
therapy is not advisable outside clinical research settings. © 1997 by Elsevier Science Inc. All rights reserved. 
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C linical staging of localized cancer is hampered 
by inaccuracy, mainly leading to understag­
ing. Consequently, most series of radical prosta-
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tectomies contain a large number of patients with 
tumors extending beyond the prostate. From this 
experience it is clear that radical surgery is feasible 
in this category of patients, Since it is known that 
a localized lesion can be reduced in size by hor­
monal treatment, the question as to whether pre­
operative hormone manipulation enhances surgi­
cal curability has remained since 1941 when the 
androgen-dependency of prostatic carcinoma was 
first described.1 With the availability of reversible 
luteinizing-hormone-releasing hormone (LHRH) 
analogs and nonsteroidal antiandrogens, interest 
in preoperative hormonal manipulation has re-
0090-4295/97/S17.0 0 
PII S0090-4295(97)00171-4 65
cently been reawakened. Presently, neoadjuvant 
hormonal manipulation in prostatic carcinoma is 
not a commonly accepted treatment. The pub­
lished clinical and pathological studies on this 
subject are conflicting.2 The importance of the 
question “Is neoadjuvant therapy really benefi­
cial?” has been shown in two conflicting articles 
published in 1993: Oesterling et al.3 concluded 
that “preoperative androgen deprivation therapy 
has little or no benefit for decreasing the extent of 
tumor or pathological stage; the concept of down- 
staging is misleading”; Fair et a l4 concluded that 
“although it is not possible to state currently that 
any patient has received benefit from neoadjuvant 
hormonal therapy, it is likewise not possible to be 
dogmatic in the assertion that neoadjuvant therapy 
is not beneficial.” Therefore, it is important that 
further clinical studies, preferentially randomized 
trials, should be performed to determine the real 
value of preoperative hormonal therapy. We 
herein report the preliminary results of such a ran­
domized trial.
MATERIALS AND METHODS
In October 1991, we started a randomized, multicenter 
study to evaluate the short- and long-term effects of neoad­
juvant hormonal treatment in prosLatic carcinoma. The pri­
mary objective of the study was to evaluate the effect of neoad­
juvant therapy on time to PSA progression. The secondary 
objectives were to compare the ease and complications of sur­
gery, the histopathologic grading and staging, and the posi- 
tivity of lymph nodes and surgical margins between both 
groups.
Patients with newly diagnosed T2-3N0M0 prostatic carci­
noma confirmed by histopathologic analysis were randomized 
for direct radical retropubic prostatectomy (DP) or neoadju­
vant combination therapy (NEO) using the LHRH analog gos- 
erelin (3.6 mg subcutaneous depot each month) plus flutam- 
ide (250 mg thrice daily) for a period of 3 months followed 
by radical prostatectomy. At randomization, patients were 
stratified for clinical T category and pathological grade of the 
tumor for each participating center. Serial PSA levels, pre- and 
post-treatment prostate volumes measured by transrectal ul­
trasound (TRUS), clinical stage before and after neoadjuvant 
therapy, and ease of surgery were investigated. The pathologic 
stage of the tumor was assessed by each local pathologist us­
ing a standardized prostatectomy step-sec lion protocol. Rad­
ical prostatectomy specimens were fixed and radially sec­
tioned in 0.5 cm thick segments from the apex lo the base 
and submitted in their entirety for histopathologic examina­
tion. All surgical specimens were classified according to the 
TNM (tumor, nodes, metastases) classification system.5 Using 
this classification, a pathologic TO (pTO) tumor was when 
there was no evidence of the primary tumor; p T l  indicated 
that the tumor was an incidental histologic finding (only mi­
croscopic foci of carcinoma); pT2 indicated that the tumor 
was present grossly but limited to the gland, while pT3 tumors 
invaded beyond the prostatic capsule or bladder neck or sem­
inal vesicle; a pT4 tumor invaded adjacent structures other 
than those listed in T3. The “clinical downstaging” percent­
ages for those who underwent neo adjuvant treatment were 
assessed. A patient was clinically downstaged if after 3 months 
of neoadjuvant treatment the clinical stage of the tumor was 
lower than the clinical stage at baseline. A patient was “path­
ologically downstaged” if the final pathologic stage was lower 
than the clinical stage at baseline.
The primary endpoint used for the determination of the 
sample size wa^ an increase of PSA >  1 ng/mL after surgery 
on two subsequent occasions. The goal was to have 200 ev­
aluable patients in each treatment arm. This estimate was 
based on the probability of detecting a 15% difference (from 
35% in the direct prostatectomy group to 20% in the neoad­
juvantly-treated group) in the number of patients that develop 
a rise in PSA during the study follow-up period of 2 years 
using a two-sided log rank test with a power of 90% and a 
type 1 error rate of 5%.
Statistical analyses were performed using the Mann-Whit- 
ney U test and chi-square test for numerical and categorical 
data, respectively. To compare the lime to PSA progression 
between both treatment arms, 95% confidence intervals (Cl) 
of the mean time of PSA progression-free survival were cal­
culated.
RESULTS
Presently, the preliminary results from 354 pa­
tients are available. Stratification for initial stage 
and grade for these patients was comparable in the 
two treatment arms. In the NEO-group, serum 
PSA levels decreased from a mean (SD) of 19.9 
(17.5) ng/mL to a mean of 0.8 (2.1) ng/mL after 3 
months of neoadjuvant therapy. After 3 months of 
neoadjuvant therapy, 40% of the patients had un­
detectable PSA levels and the prostatic volume, as 
assessed by ultrasound, had decreased from a 
mean of 38 (19) cm3 to a mean of 26 (15) cm3 
(30% decrease). The mean duration of surgery and 
blood loss were not significantly different (P = 
0.16 and P = 0.93, respectively). The mean hos­
pitalization time was 17 days in the DP group and 
16 days in the NEO group (P = 0.71). The re­
ported nature, severity, and incidence of compli­
cations (17% of the patients in the NEO group; 
18% in the DP group) occurring within 30 days 
postoperatively was not significantly different (P
= 0.83).
Table I demonstrates the initial clinical stage 
compared with the final histopathologic stage after 
surgery for both treatment groups. In the NEO 
group, “clinical downstaging” was seen in 53 out 
of 164 patients (32%) after 3 months of neoaclju- 
vant therapy prior to surgery. In the NEO group 
and the DP group, “pathologic downstaging” was 
seen in 26 out of 164 patients (16%) and in 11 out 
of 190 patients (6%), respectively. The difference 
in pathologic downstaging percentages between 
both groups was statistically significant (P <0.01). 
Cancer could not be found in the prostatectomy 
specimen in 4 of the 164 patients who were treated 
neoadjuvantiy. Initially, we had 6 patients who ap­
peared to be downstaged to pTO. One patient with 
a clinical T2 tumor, in whom no tumor could be 
found in the radical prostatectomy specimen after 
the first pathologic examination using step-sec­
tioning of the entire prostate, was reviewed by the
TABLE I. Final histopathological stage after surgery compared with the initiaf 
clinical stage at diagnosis
pTONO pT1 NO p T 2N 0 p T 3 N 0 p T 4 N 0 pTxN-f-
Neo T2 (n = 92) 3 (3%) 5 (6%) 53 (58%) 25 (27%) 2 (2%) 4 (4%)
Dir 12 (n = 107) --- 2 (2%) 34 (32%) 51 [47%) 3 (3%) 17 (16%)
Neo T3 (n = 72) 1 (1%) 17 (24%) 34 (47%) 3 (4%) 17 (24%)
Dir T3 (n - 83) --- 9 (11%) 43 (52%) 4 (5%) 27 (32%)
Dir, Direct prostatectomy group; Neo, neoadjuvant-treated group.
local pathologist. Immunohistochemical exami­
nation (prostatic acid phosphatase [PAP] and 
PSA) revealed a residual focus of carcinoma. In 
another patient who was downstaged to pTO ac­
cording to the local pathologist, another patholo­
gist who used the same slides recognized a small 
focus of carcinoma. The high understaging per­
centages are remarkable: 102 out of 190 patients 
(54%) in the DP group and 51 out of 164 patients 
(31%) in the NEO group. There were significantly 
more patients understaged in the DP group (P 
C.01). Lymph-node-positive disease was found 
in 21 out of 164 patients treated neoadjuvantly 
and in 44 out of 190 patients in the DP group. This 
difference in favor of the neoadjuvant group is sta­
tistically significant (P — 0.01). In the NEO group, 
the proportions of patients with organ-confined 
and specimen-confined disease were 45% and 
24%, respectively. In the DP group, these percent­
ages were 21% and 25%, respectively, indicating a 
significant difference in favor of the neoadju­
vantly-treated patients (P <0.01). The effect of 3 
months neoadjuvant combination therapy on pos­
itive margins after prostatectomy is indicated in 
Table II.
PSA follow-up data for the comparison of the 
time to PSA progression between both treatment 
arms were available from 215 patients with a mean 
follow-up time of 15 months. In the DP group, 25
out of 108 patients (23%) experienced an increase 
of PSA >1 ng/mL after surgery on two subsequent 
occasions. The mean time of PSA progression-free 
survival in this group was 32.5 months (95% Cl: 
28.1 to 36.9 months). In the NEO group, 24 out 
of 107 patients (22%) had an increasing PSA. The 
mean time of PSA progression-free survival in this 
group was 30.8 months (95% Cl: 26.4 to 35.1 
months).
COMMENT
Our results confirm the results described in lit- 
erature. After 3 months of neoadjuvant treatment, 
clinical downstaging in one-third of the patients 
occurs, but clinical downstaging cannot always be 
confirmed pathologically. Pathologic downstaging 
occurred in a significantly larger percentage in the 
neoadjuvantly-treated group. The clinical rele­
vance of the statistically significant higher num­
bers of patients with pathologic downstaging after 
neoadjuvant treatment must be confirmed when 
further follow-up allows an evaluation on time to 
PSA progression. Pathologic downstaging can be a 
consequence of phenotypic changes of tumor cells 
that makes recognition of them as persisting can­
cer cells difficult.6 The pathologist should be aware 
of phenotypic changes because the atrophic cells 
can easily be confused with lymphocytes, resulting
TABLE II. Effect of 3 month neoadjuvant combination therapy on
positive margins after radical prostatectomy
No Radical
Negative
Margins
(% )
Positive
Margins
(% )
Prostatectomy 
(N+ disease) 
( % )
Neo T2 (n = 92) 79 (86%) 13 (14%) —
Dir T2 (n - 107) 66 (62%) 38 (36%) 3 (2%)
Neo T3 (n = 72) 38 (53%) 31 (43%) 3 (4%)
Dir T3 (n = 83) 31 (37%) 49 (59%) 3 (4%)
Total Neo (n = 164) 117 (71%) 44 (27%) 3 (2%)
Total Dir (n = 190) 97 (51%) 87 (46%) 6 (3%)
Neo, Neoadjuvant group; Dir, direct prostatectomy group.
Comparison of neoadjuvant group versus direct prostatectomy group in patients, with a clinical T2 Uimor: P <.01. 
Ctiinparisim of neoadjuvant group versus direct prostatectomy group in patients wi£h a clinical T3 tumor: P = .14. 
Cüfnpfln'son of both cT2 and cT3 neoadjuvant groups versus direct, prostatectomy groups: P <.01.
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in false negative histologic results. Immunostain- 
ing of tumor cells and the use of monoclonal an­
tibodies against specific cytokeratins can be very 
helpful to detect immunohistochemically-persist- 
ing tumor cells and positive margins.7 These new 
pathology tools were only occasionally used in our 
study. For an accurate evaluation of the real value 
of false-negative histologic results, it would be 
worthwhile to standardize pathologic review and 
use immunostaining or monoclonal antibodies 
against specific cytokeratins throughout the study. 
Unfortunately, this was not feasible in the present 
study. Edelstein et a l H retrospectively investigated 
the lymph nodes of 36 patients who underwent a 
radical prostatectomy. In these patients, clinical 
follow-up was available using reverse transcriptase 
polymerase chain reaction (RT-PCR) /esults, 
which demonstrated PSA mRNA activity in the 
lymph nodes of 16 out of 36 (44%) patients. It was 
remarkable that 14 out of 16 patients developed a 
rise of PSA, demonstrating that using conventional 
pathologic examination, it is likely that we miss a 
percentage of microscopic lymph node metastases. 
This may also account for the detection of pros­
tatic cancer in surgical margins. Using neoadju­
vant treatment it may be even more difficult to 
identify prostatic cancer cells. The distribution of 
the tumor grade categories in the NEO group was 
not significantly different when compared with the 
DP group. Hence, a statistically significant lower 
incidence of lymph-node-positive disease in the 
NEO group fastens suspicion on a false-negative 
histologic examination rate in the neoadjuvantly- 
treated group if it turns out that this does not 
translate into a longer PSA progression-free sur­
vival time.
The prostatic volume after 3 months of neoad­
juvant treatment decreased from a mean of 37.7 
to 26.5 cm3. This important downsizing could 
result in a decreased num ber of complications 
during and after surgery. The literature is con­
tradictory on whether neoadjuvant therapy does 
or does not complicate the prostatectomy itself. 
Macfarlane et al.9 and Soloway et a h 10 reported 
no change in blood loss and operative time, but 
van Poppel et al.11 reported a greater incidence 
of complications and blood loss. Schulman12 re­
ported less blood loss and shorter operating 
time. In our series, significant advantages in fa­
vor of the neoadjuvantly-treated group could not 
be detected when looking at surgery time, blood 
loss during surgery, hospitalization period, and 
complication rate. It is noteworthy that the hos­
pitalization time in European countries still 
largely exceeds the duration of hospital stay in 
the USA.
When comparing the number of positive mar­
gins after prostatectomy in both groups, a signifi­
cant advantage in the NEO group was seen (P 
<0.01). When looking at the clinical T2 (cT2) 
group, this advantage is significant (P <0.01). 
When evaluating the clinical T3 group, a statisti­
cally significant advantage in number of positive 
margins could not be shown (P = 0.14). These 
results are in accordance with the results of a study 
reported by van Poppel et a/.11 A significant de­
crease in the number of patients with positive mar­
gins in favor of the NEO group has also been re­
ported by Labrie et ah,13 Goldenberg et al.,14 and 
Soloway et ah,10 all of whom investigated the ef­
fects of neoadjuvant treatment mainly in patients 
with clinical organ confined (cT stage ^ 2 )  tumors. 
In our study in patients with a clinical T2 tumor, 
at least one surgical margin was positive in 14% of 
the patients who underwent neoadjuvant treat­
ment, compared to 36% of the controls. These re­
sults are comparable to the 13% and 38% rates, 
respectively, obtained by Labrie et a!.,13 but differ 
from those of a randomized study by Goldenberg 
et a l  who, using cyproterone acetate for neoad­
juvant treatment, reported a difference of 37% in 
the rate of positive surgical margins between 
treated patients (positive margin rate 28%) and 
untreated controls (positive margin rate 65%).14 
Soloway et al. reported positive margins in 18% 
and 48%, respectively.10 Oesterling et a l  found 
higher rates (86%) of positive margins in patients 
who had received some type of preoperative an­
drogen deprivation. Most of these patients had 
stage cT3 cancer, so the implications for patients 
with apparently less extensive cancers are un­
clear.3
The mean time of progression-free survival 
showed no significant differences between treat­
ment groups. However, we must be cautious in 
drawing conclusions from an analysis that is pre­
liminary because the number of evaluable patients 
needed in this study is 400. We only have 215 
patients at this time for the evaluation of the time 
of PSA progression-free survival.
Realizing that there is a strong relationship be­
tween tumor volume, seminal vesicle invasion, 
the extent of capsular invasion, and metastases, 
it is likely that the benefit of neoadjuvant hor­
monal treatment, if any, lies in a decrease of pos­
itive margins in a subgroup of patients with clin­
ical Tl-2 tumors, resulting in an enhanced local 
control and possibly also survival. The benefit of 
neoadjuvant hormonal treatment in patients 
with clinical T3 tumors remains controversial. 
Further follow-up is necessary to provide the 
still-lacking information on both local effects 
and survival advantages of neoadjuvant hor­
monal manipulation in prostatic carcinoma. 
Presently, neoadjuvant therapy is not advisable 
outside clinical research settings.
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Hospital Foch, Suresnes, France; Mr. A.C. Buck, Glasgow 
Royal Infirmary, Glasgow, U.K.; Prof.dr. P.J. van Cangh, Cli- 
niques Universitaires St, Luc, Brussels, Belgium; Dr. Carbal- 
lido, Las Norias, Madrid, Spain; Mr. H J. Duncan, Border Urol­
ogy Clinic, Albury, Australia; Dr. U. Ferrando, Molinette 
Hospital, Torino, Italy; Dr. J. Flamm, Krankenhaus St. Pölten, 
St, Pölten, Austria; Prof.dr. D. Fontana, Ospedale S. Luigi 
Gonzaga, Orbassono-Torino, Italy; Dr.med. G. Forster, Urol- 
ogische Klinik Planegg, Planegg (b. Munich), Germany; 
Prof.dr. W. Höltl, Kaiser-Franz-Josef-Spital der Stadt Wien, 
Vienna, Austria; Dr. S.'Horenblas, A. van Leeuwrenhoekhuis, 
Amsterdam, The Netherlands; Prof.dr. P. Puppo, Santa Co­
rona Hospital, Pietra Ligure (SV), Italy; Prof.dr. M. Rizzo, 
Università di Firenze, Florence, Italy; Dr. H.E. Schaafsma, 
Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands; 
Prof.dr. F.P. Selvaggi, University of Bari, Bari, Italy; Dr. C. 
Sternberg, Roma, Italy; Prof.dr. E. Usai, Ospedale SS Trinità, 
Cagliari, Italy; Prof.dr. H. Villavicencio, Fundación Puigvert, 
Barcelona, Spain; and Dr.G.E. Voges, Johannes-Gutenberg- 
Uni versi tat, Mainz, Germany.
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